Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Operating Income
Apontis Pharma AG
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Operating Income
-€9.6m
|
CAGR 3-Years
-171%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Operating Income
-$122.3m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Operating Income
€2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-10%
|
|
|
Merck KGaA
XETRA:MRK
|
Operating Income
€3.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Operating Income
€206.1m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Operating Income
€24.6m
|
CAGR 3-Years
19%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Operating Income?
Operating Income
-9.6m
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Operating Income amounts to -9.6m EUR.
What is Apontis Pharma AG's Operating Income growth rate?
Operating Income CAGR 3Y
-171%
The average annual Operating Income growth rates for Apontis Pharma AG have been -171% over the past three years .
You don't have any saved screeners yet